Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 2Phase 2 1

Status

Completed 3Recruiting 2Terminated 1

Sponsor Class

OTHER 18INDUSTRY 6

Study Type

Interventional 6Observational 3

Sponsor

Cancer Type

Genitourinary 6

Conditions

Neoplasms 2870Carcinoma, Non-Small-Cell Lung 2420Breast Neoplasms 2065Colorectal Neoplasms 1239Neoplasm Metastasis 1223Prostatic Neoplasms 1076Melanoma 972Multiple Myeloma 960Ovarian Neoplasms 899Recurrence 849Leukemia, Myeloid, Acute 807Lung Neoplasms 756Pancreatic Neoplasms 750Lymphoma, Non-Hodgkin 726Lymphoma 660Stomach Neoplasms 622Carcinoma, Hepatocellular 564Carcinoma, Renal Cell 544Squamous Cell Carcinoma of Head and Neck 525Leukemia, Lymphocytic, Chronic, B-Cell 493Lymphoma, Follicular 468Head and Neck Neoplasms 449Glioblastoma 435Advanced Solid Tumors 430Small Cell Lung Carcinoma 408Triple Negative Breast Neoplasms 407Lymphoma, Large B-Cell, Diffuse 398Leukemia 394Uterine Cervical Neoplasms 367Advanced Solid Tumor 349

Interventions

disitamab vedotin 1dactolisib 1VT-464 1NVP-BKM120 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Castration-resistant Prostate Cancer × Clear all
NCT07259213 2026-04-01

RAD402

Radiopharm Theranostics, Ltd

Phase 1/2 Recruiting
73 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT06227156 2024-05-23

Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer

RemeGen Co., Ltd.

Phase 2 Recruiting
40 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT03136640 2021-10-19

ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer

Modra Pharmaceuticals

Phase 1 Completed
23 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT03514836 2021-02-01

A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer

Sotio Biotech Inc.

Phase 1/2 Terminated
5 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT01634061 2020-12-09

Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients

Novartis

Phase 1 Completed
43 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT02361086 2019-02-01

A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

Innocrin Pharmaceutical

Phase 1/2 Completed
21 enrolled
Genitourinary

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡